Authors' conclusions
There were no data from randomised controlled or quasi-randomised trials that evaluated the effect of intrapartum instillation of pharyngeal surfactant before the first breath. Evidence from animal and observational human studies suggest that pharyngeal instillation of surfactant before the first breath is potentially safe, feasible and may be effective. Well designed trials are needed.
P L A I N L A N G U A G E S U M M A R Y
Pharyngeal instillation of surfactant before the first breath for prevention of morbidity and mortality in preterm infants at risk of respiratory distress syndrome There is no current evidence from clinical trials to guide the use of pharyngeal instillation of surfactant before the first breath in preterm infants at risk of respiratory distress syndrome.
Respiratory distress syndrome is caused by a deficiency of natural lung detergent (surfactant) and occurs mainly in infants born before term (37 weeks' gestation). The usual treatment includes instilling artificial surfactant directly into the newborn infant's airway followed by mechanical ventilation. However, this process can lead to lung injury which may affect the infant's long-term health. A potential alternative strategy is to instil surfactant into the posterior pharynx as soon as the baby's head appears, just before delivery of the shoulders. Thereafter, resuscitation measures are instituted as usual. This procedure has the potential to reduce the need to support the infant's breathing after birth, as well as any lung damage caused by mechanical ventilation. We did not find any trials for this review of pharyngeal instillation of surfactant before the first breath in preterm infants at risk of respiratory distress syndrome. In view of the encouraging results from animal studies and preliminary human studies, trials of pharyngeal instillation of surfactant before the first breath in preterm infants at risk of respiratory distress syndrome are needed.
B A C K G R O U N D Description of the condition
Respiratory distress syndrome (RDS) results from a deficiency of pulmonary surfactant and is a significant cause of morbidity and mortality in preterm infants. Randomised controlled trials and meta-analyses have demonstrated the efficacy of surfactant therapy in both the prevention and treatment of infants with, or at risk of, RDS. Studies have compared a wide variety of surfactant preparations. These include synthetic surfactants (Soll 1998a; Soll 1998b ) and surfactants derived from animal sources (natural surfactants) (Seger 2009; Soll 2002) . Although both synthetic and animal-derived surfactant preparations are effective (Soll 1998a; Soll 1998b; Soll 2002; Seger 2009 ), clinical trials suggest that animalderived surfactant may be more effective (Soll 2001a ) than protein-free synthetic surfactant (Tooley 1987) . Furthermore, clinical trials have shown prophylactic surfactant (Soll 1998b; Soll 2001b; Soll 2002 ) and early surfactant (Soll 1999; Stevens 2007) are superior to selective use of surfactant in preventing morbidity and mortality in preterm infants. The trials also suggest that a multiple-dose strategy is superior to a single-dose strategy ). Tests also point to the successful use of new protein-containing synthetic surfactants (Pfister 2007) although these preparations are not currently available for clinical use. Despite the benefits of surfactant, many infants develop bronchopulmonary dysplasia (BPD) and chronic lung disease (CLD). Although the aetiology of CLD in preterm infants is multifactorial (Allen 2003), ventilator-induced lung injury (VILI) remains one of the main implicated risk factors (Coalson 1999; Clark 2000) . We know that only a few resuscitative positive pressure ventilation (PPV) breaths may result in VILI (Grossmann 1986; Björklund 1997; Fleckonoe 2008; O'Reilly 2008) . Both surfactant prophylaxis and therapy necessitate endotracheal intubation to facilitate surfactant administration. Although surfactant by itself is an established, effective intervention for either the prevention or treatment of RDS (Soll 1998a; Soll 1998b; Soll 1999; Soll 2001a; Soll 2001b; Soll 2002; Stevens 2007; Seger 2009; ), endotracheal intubation and the subsequent use of PPV are not without side effects. Endotracheal intubation is a potentially traumatic procedure that is often performed without optimal pain management (Sarkar 2006) . It may be accompanied by significant haemodynamic instability including hypoxia, bradycardia, blood pressure fluctuation and an intracranial pressure increase (Marshall 1984; Ghanta 2007) . Intubation is inevitably associated with colonisation of the trachea, retained secretions resulting in collapse, differential aeration and high resistance to air flow, resulting in increased work of breathing and potentially leading to nosocomial pneumonia and sepsis (Young 2005; Aly 2008) . Intubation is associated with an inflammatory process which can lead to lung injury and BPD (Young 2005) . Current evidence suggests PPV of immature, surfactant-deficient lungs is harmful and may exacerbate the development of BPD (Björklund 1997; Van Marter 2000) . Björklund reported that resuscitation of surfactant-deficient immature lambs with as few as six breaths damages the lungs and blunts the therapeutic effect of subsequent surfactant replacement (Björklund 1997) . Grossmann 1986 reported similar results. Fleckonoe 2008 reported that just six hours of ventilation were enough to cause marked airway epithelial injury in very preterm and near-term fetal sheep. O'Reilly 2008 reported that ventilator-induced injury extends to involving the conducting airways as well. One approach to surfactant administration is the InSurE (INtubation-SURfactant-Extubation) technique pioneered by Victorin (Victorin 1990) and Verder (Verder 1994) . A review of trials found that early surfactant replacement therapy with prompt extubation to nasal continuous positive airway pressure (nCPAP), as in the InSurE technique, is associated with less need for mechanical ventilation, lower incidence of BPD and fewer air leak syndromes when compared with later, selective surfactant replacement and continued mechanical ventilation with extubation from low ventilator support (Stevens 2007) . However, the limited data available show the InSurE procedure to be associated with a propensity for decreased cerebral oxygenation, higher cerebral oxygen extraction and decreased electric brain activity (Hellström-Westas 1992; van de Berg 2000) . Furthermore, the InSurE procedure may need to be repeated if the first dose of surfactant was not sufficiently effective (Bohlin 2007), leading to additional risk of brain damage. The main strategy used to avoid endotracheal intubation and PPV in premature infants is application of nCPAP or continuous distending pressure (CDP) immediately following birth (Kamper 1999; Ho 2002a; Ho 2002b) . Recent studies suggest CDP may lead to less CLD compared to elective intubation, surfactant and PPV (Aly 2001; de Klerk 2001) . Similarly, nasal intermittent positive pressure ventilation (NIPPV) has shown a decreased need for intubation and mechanical ventilation. It also reduces the frequency of apnoea and the incidence of CLD without an increase in adverse effects (Davis 2001; Lemyre 2002) . Although CDP and NIPPV strategies avoid endotracheal intubation and PPV they preclude surfactant administration, which is a standard and proven treatment for RDS. Furthermore, CDP, NIPPV and InSurE may fail in 25% to 50% of preterm infants (Reininger 2005; Kugelman 2007; Morley 2008) .
Description of the intervention
Non-invasive methods of surfactant administration have the potential to reduce the need for intubation and endotracheal surfactant administration. Potential strategies include:
1 (Jorch 1997) . This review focuses on pharyngeal instillation of surfactant. The typical protocol for pharyngeal instillation of surfactant is as follows (Kattwinkel 2002; Kattwinkel 2004) : as soon as the baby's head appears on the perineum or at the operative incision, the mother is instructed to stop pushing and the pharynx and stomach are suctioned with a catheter. A surfactant solution is then instilled into the posterior pharynx through a catheter without direct laryngoscopy. The baby is stimulated to breathe spontaneously as soon as the shoulders and rest of the body are delivered. Thereafter, resuscitation measures are instituted as usual.
How the intervention might work
Pharyngeal instillation of surfactant is designed to administer surfactant to the surfactant-deficient lungs by taking advantage of the normal physiology of establishing breathing air. While the chest remains compressed in the birth canal, fetal lung fluid is suctioned from the future upper airway and is replaced with a surfactant-containing solution. The chest expands as it is released into the vaginal vault and beyond and the baby is stimulated to aspirate the surfactant-containing solution, providing surfactant at the advancing air-fluid interface. The technique is designed to avoid endotracheal intubation whilst offering the benefits of surfactant administration. Combining pharyngeal surfactant administration with prenatal steroid administration and CDP offers potential synergy to treat RDS, avoiding both endotracheal intubation and PPV, thereby reducing lung injury that may lead to BPD. Animal studies in rabbits and lambs indicate that surfactant deposition into the posterior pharynx before the first breath permits aspiration of surfactant at initiation of ventilation, improves expansion of the lungs and prolongs survival (Enhorning 1973; Cummings 1995) . Furthermore, animal studies have shown that surfactant is more uniformly distributed (Jobe 1984) and pulmonary function maintained for a longer time (Cummings 1995) if surfactant is delivered to fluid-filled rather than air-filled lungs.
Despite significant advances in neonatal intensive care, CLD results in a significant health burden to preterm infants born at less than 32 weeks' gestation who received mechanical ventilation. CLD results in substantial neonatal and infant morbidities and health resource utilisation (Allen 2003) . It is associated with chronic respiratory difficulties (Kilbride 2003; Doyle 2006); prolonged and recurrent hospitalisation (Chye 1995); neurodevelopmental disabilities including cerebral palsy, neurosensory and motor disabilities (Skidmore 1990; Singer 1997; Majnemer 2000) and poor cognitive outcome (Hughes 1999). CLD has a major impact on the daily lives of families, which persists beyond the neonatal period (Korhonen 1999) . Pharyngeal instillation of surfactant before the first breath is a physiologic and logical technique with the potential benefit of avoiding ventilation, VILI and possibly BPD.
O B J E C T I V E S
To determine the effect of pharyngeal instillation of surfactant before the first breath compared to placebo, no treatment or intratracheal surfactant administration followed by intermittent positive pressure ventilation (IPPV) on morbidity and mortality in preterm infants at risk of RDS.
M E T H O D S Criteria for considering studies for this review

Types of studies
Trials using randomisation or quasi-randomisation of patients regardless of the unit of allocation (individual or cluster) were eligible for inclusion. Published or unpublished and ongoing studies were eligible for inclusion.
Types of participants
Participants were mother-infant dyads. We included preterm infants of less than 32 completed weeks' gestation that were at risk of RDS. Infants should have had the intervention attempted before the first breath to be eligible.
Types of interventions
Pharyngeal instillation of surfactant, attempted before the first breath at any dose and using any type of surfactant (synthetic, animal-derived or protein-containing synthetic), compared with placebo, no treatment or intratracheal instilled surfactant. We planned to perform separate comparisons for all the above groups.
Types of outcome measures Primary outcomes
Primary outcome measures included:
1. chronic lung disease (CLD), defined as need for oxygen or respiratory support at 36 weeks postmenstrual age (PMA); 2. mortality prior to hospital discharge; 3. neurodevelopmental disability at a minimum of 18 months postnatal age, defined as neurological abnormality including cerebral palsy on clinical examination, developmental delay of more than two standard deviations below the population mean on a standardized test of development, blindness (visual acuity less than 6/60) or deafness (any hearing impairment requiring amplification) at any time after the age was term corrected.
Secondary outcomes
Secondary outcome measures included other measures of effectiveness, complications, satisfaction with care and health service use for both women and infants. These included any of the following. 
Searching other resources
We carried out additional searches as follows. 3. Reference lists. After reading the identified individual studies that examined the effect of pharyngeal surfactant installation on morbidity and mortality in preterm infants at risk of RDS, we screened the reference lists of these papers to identify other relevant studies 4. Personal communications with expert informants and authors of included studies. 5. Pharmaceutical companies. We contacted the company (Abbott Laboratories, Inc) that developed different types of surfactant for possible unpublished studies using their products.
Data collection and analysis
We planned to use the standardized review method of the Cochrane Neonatal Review Group (CNRG) for conducting a systematic review (http://neonatal.cochrane.org/en/index.html). We planned to enter and cross-check data using Review Manager 5 software (RevMan 2008).
Selection of studies
Both review authors independently assessed study eligibility for inclusion in this review. We retrieved full text versions for potentially eligible studies when the abstract provided inadequate information.
Data extraction and management
Both review authors independently extracted data from the fulltext articles using specifically designed spreadsheets to manage the information. We planned to use these forms to decide on trial inclusion and exclusion, extract data from eligible trials and to request additional published information from authors of the original reports. We planned to compare the extracted data for any differences. If noted, we planned to resolve differences through mutual discussion and consensus.
Assessment of risk of bias in included studies
We planned to use the standardized review methods of The Cochrane Collaboration to assess the methodological quality of studies (Higgins 2008) . The review authors planned to independently assess the quality and risk of bias of the potential studies based on the following six domains: 1) sequence generation; 2) allocation concealment; 3) blinding of participants, personnel and outcome assessors; 4) incomplete outcome data; 5) selective outcome reporting; 6) other sources of bias. When necessary, we planned to request additional information and clarification of published data from the authors of individual trials. We planned to assess each trial for risk of bias based on the criteria listed above and mark as: a) low risk of bias; b) unclear risk of bias; c) high risk of bias. We planned to resolve discrepancies by consensus and to report any persisting discrepancies.
Measures of treatment effect
We planned to report dichotomous data using relative risk (RR) and risk difference (RD) with 95% confidence intervals (CI). If there was a statistically significant reduction in RD we planned to calculate the number needed to treat (NNT) and associated 95% CI. We planned to report mean differences with 95% CI for continuous outcomes.
Unit of analysis issues
The unit of randomisation is the intended unit of analysis and is expected to be individual infants.
Cluster-randomised trials
We planned to include cluster-randomised trials in the analyses along with individually randomised trials. We planned to analyse them using the methods described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2008) using an estimate of the intra-cluster correlation coefficient (ICC) derived from the trial (if possible) or from another source. If we use ICCs from other sources, we planned to report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-randomised trials and individually-randomised trials, we planned to synthesise the relevant information. We considered it reasonable to combine the results from both if there is little heterogeneity between the study designs and interaction between the effect of intervention and the choice of randomisation unit is unlikely.
Dealing with missing data
We planned to obtain missing data from the authors, when possible. If this is not possible, we planned to conduct analyses on available data (that is ignoring the missing data). In addition, we planned to conduct another analysis by using imputation methods (both best and worst scenarios) and last observation carried forward (LOCF) to the final assessment method for dichotomous and continuous outcome data, respectively. For dichotomous outcomes we planned to conduct both best and worst scenarios and intention-to-treat (ITT) analysis with imputation. We planned to compare results obtained from two analysis options to arrive at a better understanding of the robustness of results relative to the different analytic approaches. We planned to consider an imputation approach of best case scenarios (that is all missing participants in the intervention group did not experience a bad outcome such as death or BPD and all missing participants in the control group experienced a bad outcome) and worst case scenarios (that is all missing participants in the intervention group experienced the event and all missing participants in the control condition did not). We planned to conduct a sensitivity analysis to compare results based on different imputation assumptions (that is best versus worst scenarios). We planned to analyse missing continuous data on an endpoint basis, including only participants with a final assessment or using LOCF to the final assessment if the trial authors reported LOCF data.
Assessment of heterogeneity
We planned to use Review Manager software version 5 (RevMan 2008) provided by The Cochrane Collaboration to assess the heterogeneity of treatment effects between trials. We planned to establish the two formal statistics described below. 1) The Chi 2 test to assess whether observed variability in effect sizes between studies was greater than would be expected by chance. Since this test has low power when the number of studies included in the meta-analysis is small, we will set the probability at the 10% level of significance.
2) The I 2 statistic to ensure that pooling of data is valid. We planned to grade the degree of heterogeneity as: 0% to 30%, might not be important; 31% to 50%, moderate heterogeneity; 51% to 75%, substantial heterogeneity; 76% to 100%, considerable heterogeneity. Where there is evidence of apparent or statistical heterogeneity, we planned to assess the source of the heterogeneity using sensitivity and subgroup analysis looking for evidence of bias or methodological differences between trials.
Assessment of reporting biases
We planned to assess reporting and publication bias by examining the degree of asymmetry of a funnel plot in RevMan 5 (RevMan 2008).
Data synthesis
We planned to perform statistical analyses according to the recommendations of the Cochrane Neonatal Review Group (CNRG) (http://neonatal.cochrane.org/en/index.html). We planned to analyse all infants randomised on an intention-to-treat basis. We planned to analyse treatment effects in the individual trials. In the first instance we planned to use a fixed-effect model to combine the data. For any meta-analyses of categorical outcomes we planned to calculate typical estimates of RR and RD, each with its 95% CI. For continuous outcomes we planned to calculate the mean difference (MD) if outcomes were measured in the same way between trials. We planned to establish the standardized mean difference (SMD) to combine trials that measured the same outcome but used different scales. Where we consider meta-analysis to be inappropriate, we planned to analyse and interpret individual trials separately.
Subgroup analysis and investigation of heterogeneity
If sufficient data were available, we planned to explore potential sources of clinical heterogeneity through the following a priori subgroup analyses:
1. dose of surfactant (same dose as intratracheal, more than intratracheal dose); 2. gestational age at delivery (less than 27, 27 to 28, 29 to 32 completed weeks' gestation); 3. type of surfactant used (synthetic, animal-derived or protein-containing synthetic).
Sensitivity analysis
If sufficient data were available, we planned to explore methodological heterogeneity through the use of sensitivity analyses. We planned to perform sensitivity analyses by excluding trials of lower quality, based on a lack of any of the following: allocation concealment, adequate randomisation, blinding of treatment, less than 10% loss to follow up.
Results of the search
The search of the sources above did not find any published, unpublished or ongoing randomised or quasi-randomised controlled trials to be considered for inclusion in this review.
Excluded studies
One non-randomised study (case series) of pharyngeal instillation of surfactant (Kattwinkel 2002; Kattwinkel 2004) was excluded.
Risk of bias in included studies
Not applicable, as no eligible studies were found meeting the inclusion criteria for this review.
Effects of interventions
There are no trials that meet the inclusion criteria for this review.
D I S C U S S I O N
Pharyngeal instillation of surfactant is designed to administer surfactant to the surfactant-deficient lung by taking advantage of the normal physiology of establishing air breathing. This technique is potentially useful for administration of prophylactic surfactant. In a feasibility study, Kattwinkel 2004 studied a non-random purposive sample of 23 preterm newborns. Generally, there was sufficient time (usually approximately 30 to 45 seconds) for the procedure during vaginal births with vertex presentations, but not vaginal breech or caesarean section. The study showed that nasopharyngeal surfactant instillation at birth appears to be relatively safe and simple to accomplish, especially for vaginal births. No major complications from the study procedure were encountered. However, a large randomised clinical trial (RCT) will be required to determine the efficacy of this technique. Fernandes 2005 discussed certain issues that need to be addressed before applying this technique in randomised trials and clinical practice.
1. Dose of surfactant: it was suggested to use a greater volume of surfactant for nasopharyngeal administration than is used for intratracheal instillation as it is unlikely that the entire dose of surfactant will be aspirated. Alternatively, a more concentrated surfactant solution for nasopharyngeal instillation could be used.
2. Quantification of the amount of surfactant aspirated: this will need to be addressed before embarking on a large RCT. Fernandes 2005 suggested using perflurocarbon-surfactant mixture, which would have the dual advantages of allowing visualization of the radio-opaque perflurocarbon on chest radiograph as well as attenuation of a pulmonary inflammatory response (von der Hardt 2002; von der Hardt 2004), which might contribute to decreased incidence of chronic lung disease.
3. Whether extremely preterm infants (especially < 28 weeks gestation) are able to muster sufficient respiratory effort to aspirate nasopharyngeal surfactant needs further evaluation.
Animal studies in rabbits and lambs indicate that surfactant deposition into the posterior pharynx before the first breath permits aspiration of surfactant at initiation of ventilation, improves expansion of the lungs and prolongs survival (Enhorning 1973; Cummings 1995) . Furthermore, animal studies have shown that surfactant is more uniformly distributed (Jobe 1984) and pulmonary function maintained for a longer time (Cummings 1995) if surfactant is delivered to a fluid-filled rather than air-filled lung.
Summary of main results
No eligible trials were identified that assessed the effect of pharyngeal instillation of surfactant before the first breath, compared to placebo, no treatment or intratracheal surfactant instillation with IPPV, on morbidity and mortality in preterm infants at risk of RDS.
Overall completeness and applicability of evidence
Since no eligible trials were identified, there is no evidence from randomised clinical trials to assess the effectiveness of pharyngeal surfactant administration in preterm infants.
Quality of the evidence
There are no trials that met the inclusion criteria for this review.
Potential biases in the review process
Searches were made for published and unpublished trials including proceeding from scientific meetings, citations of studies and reviews, expert informants, trial registries and surfactant manufacturers. No trials were found that met the inclusion criteria for this review.
Agreements and disagreements with other studies or reviews
There are no trials that met the inclusion criteria for this review. 
A U T H O R S ' C O N C L U S I O N S Implications for practice
There is no evidence from randomised clinical trials to support or refute the use of intrapartum instillation of pharyngeal surfactant. The use of pharyngeal instillation of surfactant should be limited to randomised controlled trials.
Implications for research
The data available from uncontrolled human and animal studies have shown a potential benefit of intrapartum pharyngeal instillation of surfactant and justify the conduct of randomised controlled trials. Infants enrolled in such trials should be stratified by gestation.
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